Multidrug-resistant Shigella infection in pediatric patients with diarrhea from central Iran

Elnaz Abbasi1,2, Hamid Abtahi3, Alex van Belkum4

  • 1Department of Microbiology & Immunology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.

Insights

This study found high rates of antibiotic resistance in Shigella species causing pediatric diarrhea in Iran. Resistance to common antibiotics like cotrimoxazole and third-generation cephalosporins is a significant concern for treatment.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Shigella species are a leading cause of pediatric diarrhea globally.
  • Increasing antibiotic resistance, particularly to fluoroquinolones and third-generation cephalosporins, complicates shigellosis management.
  • This study investigated Shigella prevalence and resistance patterns in central Iran.

Purpose of the Study:

  • To determine the prevalence of Shigella species in pediatric diarrhea cases in central Iran.
  • To characterize the antibiotic resistance patterns of isolated Shigella strains.
  • To identify the presence of specific resistance genes, including ESBL and AmpC.

Main Methods:

  • Pediatric diarrhea samples (n=230) were analyzed using bacterial culture and genus-specific PCR (ipaH).
  • Antibiotic susceptibility testing was performed on Shigella isolates.
  • Phenotypic and genotypic analysis for Extended-Spectrum Beta-Lactamase (ESBL) and AmpC resistance was conducted.

Main Results:

  • Shigella was detected in 11.3% of samples by PCR, with Shigella sonnei and Shigella flexneri being most common.
  • High resistance rates were observed for cotrimoxazole (100%), ampicillin (84.2%), cefixime (68.4%), and ceftriaxone (63.1%).
  • ESBL genes (blaTEM, blaCTX-M-1, blaCTX-M-15) and AmpC genes (blaCMY-2) were frequently detected. Resistance to ciprofloxacin was also noted.

Conclusions:

  • A significant prevalence of Shigella with high levels of antibiotic resistance was found in pediatric patients.
  • Resistance to third-generation cephalosporins (ESBL producers) and fluoroquinolones like ciprofloxacin is a serious public health concern.
  • Effective treatment strategies for pediatric shigellosis require careful consideration of local antibiotic resistance data.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
269
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
198
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
260
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
645
The Central Dogma01:25

The Central Dogma

Overview
139.1K